DYADIC INTERNATIONAL INC. - COMMON STOCK

Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal

14 ديسمبر 2022 08:30:00 بحسب Nasdaq GlobeNewswire

Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments

10 نوفمبر 2022 16:00:00 بحسب Nasdaq GlobeNewswire

Dyadic to Present at Upcoming Industry and Investor Events in November

07 نوفمبر 2022 08:30:00 بحسب Nasdaq GlobeNewswire

Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

27 أكتوبر 2022 16:30:00 بحسب Nasdaq GlobeNewswire

Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

27 أكتوبر 2022 09:04:29 بحسب Nasdaq GlobeNewswire

Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential

04 أكتوبر 2022 08:45:06 بحسب Nasdaq GlobeNewswire

Dyadic Updates Market on Recent Scientific Achievements

13 سبتمبر 2022 08:00:02 بحسب Nasdaq GlobeNewswire

Dyadic to Present at Upcoming Industry and Investor Events in September

08 سبتمبر 2022 08:30:00 بحسب Nasdaq GlobeNewswire

Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments

10 أغسطس 2022 16:00:00 بحسب Nasdaq GlobeNewswire

Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

27 يوليو 2022 16:30:00 بحسب Nasdaq GlobeNewswire

Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL National Meeting

05 يوليو 2022 08:30:00 بحسب Nasdaq GlobeNewswire

Dyadic to Participate in Three Upcoming Industry Events

09 يونيو 2022 09:09:20 بحسب Nasdaq GlobeNewswire

Dyadic to Present at 2022 Jefferies Healthcare Conference

02 يونيو 2022 09:27:39 بحسب Nasdaq GlobeNewswire

Dyadic to Present at H.C. Wainwright Global Investment Conference

20 مايو 2022 08:30:00 بحسب Nasdaq GlobeNewswire

Dyadic Reports First Quarter 2022 Financial Results and Highlights Recent Company Developments

12 مايو 2022 16:00:00 بحسب Nasdaq GlobeNewswire

Dyadic Announces Research, License and Collaboration for the Manufacture of Animal Free Ingredients

11 مايو 2022 08:30:00 بحسب Nasdaq GlobeNewswire

Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”

09 مايو 2022 08:30:00 بحسب Nasdaq GlobeNewswire

Dyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

28 أبريل 2022 16:30:00 بحسب Nasdaq GlobeNewswire

Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform

13 أبريل 2022 08:52:30 بحسب Nasdaq GlobeNewswire

Dyadic International to Present at Upcoming Scientific Medical Meetings

04 أبريل 2022 08:30:00 بحسب Nasdaq GlobeNewswire